Cosmos Health reports record Q2 revenue of $19 million
Cosmos Health boosted investor optimism by announcing second-quarter revenue of $19 million.
The current price of $0.21 is above the $0.18 support level and below the $0.25 resistance level, placing it in the middle of the trading range. The RSI of 58.5 is neither in oversold nor overbought territory, and trading volume is 0.78 times the 20‑day average, indicating low risk of sharp volatility. Considering these factors, we are evaluating a buy.
If the stock price reaches the resistance level of 0.25, sell at the target price of $0.25 to realize profit, and if the stock price falls to the support level of 0.18, sell at the stop-loss price of $0.18. This condition is based on the resistance and support grounds presented by REPORTING.
RSI(14) 58.5, moving averages not aligned, trading volume 0.78 times the 20‑day average, recent 7‑day change –11.2% – RSI is neutral, misaligned moving averages indicate an unclear trend, low volume and negative change suggest short‑term weakness, but the price remains above support.
While there are no directly comparable cases, one can refer to instances where buying between support and resistance within a trading range led to reaching the target price.
Compared to the projected return of 4.5%, the actual return significantly exceeded at 10.2%. The target price and stop‑loss settings were appropriate, allowing profit to be realized near the resistance level. However, the low trading volume and short‑term downtrend were not reflected in the forecast, necessitating additional risk awareness.
In the next trade, we will more closely monitor low trading volume and short-term volatility, and set the stop‑loss slightly below the current support level when entering a box range to prepare for a sharp decline. Additionally, we will continuously check the theme news flow to identify positive factors and risks early.